Overview: Chromosome Analysis Neonatal High Resolution Panel
Introduction: The Chromosome Analysis Neonatal High Resolution Panel is a diagnostic tool designed for high-resolution neonatal screening using whole blood samples. In India, high-resolution karyotyping (550+ bands) detects subtle structural rearrangements missed by standard karyotyping, crucial for neonates with dysmorphism, developmental delay, or congenital anomalies. High burden of chromosomal disorders in newborns, underdiagnosis in rural deliveries, limited advanced cytogenetics access. Per cytogenetics practices aligned with ICMR and Indian Academy of Pediatrics guidelines, the test employs extended culture and high-resolution banding over 1-2 days with enhanced sensitivity, valuable for precise neonatal evaluation. This diagnostic falls under neonatal screening and targets newborns with suspected chromosomal conditions, addressing accurate detection to guide management and counseling. With elevated morbidity due to under-screening, the test supports public health efforts by enabling precise identification and reducing disability. Its whole blood-based approach ensures reliable high-resolution analysis.
Other Names: Neo Karyo Pnl.
FDA Status: FDA approved, CLIA certified for cytogenetics, compliant with 2025 standards.
Historical Milestone: High-resolution banding advanced; in India, used in specialized pediatric genetics.
Purpose: The test performs 2 parameters including high-resolution karyotype to guide detection of subtle chromosomal abnormalities, identify changes, inform management.
Test Parameters: 1. High-Resolution Karyotype, 2. Chromosomal Abnormalities.
Pretest Condition: No fasting required; newborns should have dysmorphism or developmental concerns.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate culture is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for karyotyping).
Medical History: Parents should provide details on newborn features, delivery complications, family genetic history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed abnormalities including developmental issues, benefits of high-resolution detection, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using high-resolution karyotyping by trained personnel to ensure sterile technique, extended culture, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or poor cell growth can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal high-resolution karyotype indicates subtle disorder, necessitating specialist input. Normal may require follow-up if features suggestive.
Specialist Consultation: Pediatric geneticists should be consulted for management.
Additional Supporting Tests: CMA or FISH for confirmation.
Test Limitations: Still limited to visible bands; comprehensive approach required.
References: Indian Journal of Pediatrics 2024, Neonatal Genetics Studies India 2023.
